Valiant Organics Limited · NSE:VALIANTORG
Valiant Organics — Q1 FY27 Earnings Presentation
22 slides from Valiant Organics's earnings presentation, Aug 21, 2026
Slide 1: Cover letter to stock exchanges: Investors' Presentation
August 21, 2026 To, To, Listing / Compliance Department Listing / Compliance Department BSE LTD National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1, Dalal Street G Block Bandra-Kurla Complex, Mumbai- 400 001 Bandra (E), Mumbai- 400 051. SCRIP CODE – 540145
Slide 2: Earnings Presentation | Q1-FY27
Earnings Presentation | Q1-FY27
Slide 3: Snapshot
SNAPSHOT One of the largest chlorophenol One of the leading manufacturer of derivatives manufacturer globally Benzene derivatives products One of the largest domestic PNA One of the few commercial players in manufacturer Ortho Anisidine and Para Anisidine Diversified client base across Amongst 1st f
Slide 4: Company Overview
Company Overview Valiant Organics Limited was incorporated in 1984 by first generation technocrats and is headquartered out of Mumbai, India. The company is focused on the manufacturing and marketing of specialty chemicals which find usage in a variety of industries, including agrochemicals, pharmac
Slide 5: Chemistries And Product Basket
Chemistries And Product Basket Q1-FY27 Revenue Share Hydrogenation Ammonolysis 54% Key Products: Industries Served: Key Products: • Ortho Anisidine Industries Served: • Dyes • Para Nitro Aniline • Para Anisidine • Dyes • Pigments • Ortho Chloro Para Nitro Aniline • IPPCA • Pigments • Pharmaceutical
Slide 6: Manufacturing Footprint
Manufacturing Footprint CHLORINATION – SARIGAM HYDROGENATION & METHOXYLATION- • Capacity: 18,000 MTPA JHAGADIA UNIT 1 • Products: PCP, OCP, 2,4 DCP, 2,6 DCP, • Capacity: 28,800 MTPA 2,4,6 TCP • Products: ONA/OA, PNA/PA, IPPCA, CONVERSION PRODUCTS AMMONOLYSIS - VAPI HYDROGENATION – JHAGADIA UNIT 2 •
Slide 7: Key Strengths
Key Strengths Domain expertise and broad Plant locations are process understanding in a Wide supply chain strategically located near variety of chemistries. The provides the continuous ports to provide a executive team is made up of availability of adequate competitive advantage, first-generation te
Slide 8: Q1-FY27 Highlights
Q1-FY27 HIGHLIGHTS Valiant Organics Limited | Q1-2027 7
Slide 9: Q1-FY27 Consolidated Financial Highlights
Q1-FY27 CONSOLIDATED FINANCIAL HIGHLIGHTS INR 2,315 Mn Operational Revenue INR 416 Mn Operating EBITDA 17.97% Operating EBITDA Margin INR 293 Mn Profit After Tax 12.66% PAT Margin INR 10.44/ Share EPS Valiant Organics Limited | Q1-2027 8
Slide 10: Q1-FY27 Operational Highlights
Q1-FY27 Operational Highlights Q1-FY27 Revenue Break-up – Chemistries • Total Revenue grew 14% YoY to INR 2,342 million, marking the highest quarterly revenue Others, 6% in the last six quarters and a full recovery from the H1 FY26 trough. • Gross Profit Margin improved to 43% from 39% YoY, supporte
Slide 11: Key Chemistries: Revenues and Sales Volumes
Key Chemistries Chlorination (INR Mn) Hydrogenation (INR Mn) Ammonolysis (INR Mn) Others (INR Mn) 1,400 1,272 533 540 180 163 460 451 1,200 1,082 1,050 530 160 140 450 REVENUES 520 431 140 1,000 440 510 94 120 430 800 500 100 420 410 490 475 478 394 600 80 480 400 60 400 470 390 40 460 380 200 20 45
Slide 12: Quarterly Consolidated Financial Performance
Quarterly Consolidated Financial Performance Particulars (INR Mn) Q1-FY27 Q1-FY26 Y-o-Y Q4-FY26 Q-o-Q Revenue from Operations 2,315 2,044 13.3% 2,178 6.3% Total Expenses 1,899 1,796 5.7% 1,913 (0.7)% EBITDA 416 248 67.7% 265 57.0% EBITDA Margins (%) 17.97% 12.13% 584 Bps 12.17% 580 Bps Other Income
Slide 13: Quarterly Standalone Financial Performance
Quarterly Standalone Financial Performance Particulars (INR Mn) Q1-FY27 Q1-FY26 Y-o-Y Q4-FY26 Q-o-Q Revenue from Operations 2,315 2,044 13.3% 2,177 6.3% Total Expenses 1,899 1,796 5.7% 1,912 (0.7)% EBITDA 416 248 67.7% 265 57.0% EBITDA Margins (%) 17.97% 12.13% 584 Bps 12.17% 580 Bps Other Income 26
Slide 14: Historical Financial Overview
HISTORICAL FINANCIAL OVERVIEW Valiant Organics Limited | Q1-2027 13
Slide 15: Historical Consolidated Income Statement
Historical Consolidated Income Statement Particulars (INR Mn) FY24 FY25 FY26 Q1-FY27 Revenue from Operations 7,231 7,188 7,388 2,315 Total Expenses 6,849 6,651 6,506 1,899 EBITDA 382 537 882 416 EBITDA Margins (%) 5.28% 7.47% 11.94% 17.97% Other Income 93 86 69 33 Depreciation 349 358 396 102 Financ
Slide 16: Historical Consolidated Balance Sheet
Historical Consolidated Balance Sheet Particulars (INR Mn) FY24 FY25 FY26 Particulars (INR Mn) FY24 FY25 FY26 EQUITY 7,293 7,253 7,594 Non-Current Assets 8,352 8,269 8,786 a) Equity Share Capital 276 280 280 a) Property, Plant and Equipment 6,297 6,437 6,791 b) Other Equity 7,017 6,973 7,314 c) Righ
Slide 17: Historical Standalone Income Statement
Historical Standalone Income Statement Particulars (INR Mn) FY24 FY25 FY26 Q1-FY27 Revenue from Operations 6,772 7,188 7,384 2,315 Total Expenses 6,376 6,651 6,502 1,899 EBITDA 396 537 882 416 EBITDA Margins (%) 5.85% 7.47% 11.94% 17.97% Other Income 29 81 69 26 Depreciation 340 358 396 102 Finance
Slide 18: Historical Standalone Balance Sheet
Historical Standalone Balance Sheet Particulars (INR Mn) FY24 FY25 FY26 Particulars (INR Mn) FY24 FY25 FY26 EQUITY 6,649 6,616 6,969 Non-Current Assets 7,818 7,750 7,793 a) Equity Share Capital 276 280 280 a) Property, Plant and Equipment 6,297 6,437 6,791 b) Other Equity 6,373 6,336 6,689 b) Right-
Slide 19: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 800 10,000 27.00% 7,231 7,188 7,388 7,500 22.00% 500 882 17.97% 332 293 5,000 17.00% 537 11.94% 12.66% 2,315 382 416 200 7.47% 12.00% 2,500 5.28% (34) (84) 7.00% - -100
Slide 20: Capital Market Information
Capital Market Information Share Price up to 30th June, 2026 30% 10% -10% -30% -50% -70% Jul-25 Aug-25 Sep-25 Oct-25 Nov-25 Dec-25 Jan-26 Feb-26 Mar-26 Apr-26 May-26 Jun-26 Valiant Organics Sensex Price Data (As of 30th June 2026) INR Shareholding pattern (As of 30th June, 2026) Face Value 10.0 FII;
Slide 21: Disclaimer
Disclaimer Valiant Organics Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all event
Slide 22: Thank You
THANK YOU Valiant Organics Limited | Q1-2027 21